GlassScriptPhysician profile
Jose Macedo
NPI 1679614127
$8,800.53
in general payments reported to CMS, 2019-2025
25 companies · $467 in 2025
The $467 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,217 · 2020: $690 · 2021: $744 · 2022: $2,239 · 2023: $1,219 · 2024: $1,224 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,847 · Entertainment: $62.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,847.33 |
| Entertainment | $62.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,692.34 | 2022-2025 | Infuse |
| Johnson & Johnson Vision Care, INC. | $1,574.67 | 2019-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,118.52 | 2019-2021 | |
| Coopervision INC. | $634.79 | 2019-2024 | Myday Contact Lens |
| Abb Con-Cise Optical Group LLC | $557.45 | 2019-2020 | |
| Maculogix, INC. | $385.73 | 2020 | |
| Visioneering Technologies, INC. | $353.33 | 2019 | |
| Sun Pharmaceutical Industries INC. | $348.82 | 2020-2024 | |
| Dompe US, INC. | $261.52 | 2024-2025 | Oxervate |
| Shire North American Group INC | $246.63 | 2019 | |
| Optos, INC. | $237.82 | 2022-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Biotissue Holdings INC. | $221.26 | 2022-2023 | |
| Topcon Healthcare, INC. | $139.84 | 2022-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $135.51 | 2023 | Lipiflow System Activator (Disposable) |
| Kala Pharmaceuticals, INC. | $124.99 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $124.16 | 2019 | |
| Sight Sciences, INC. | $123.57 | 2022 | |
| Horizon Therapeutics Plc | $117.76 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $117.18 | 2024-2025 | |
| Lkc Technologies, INC. | $85.77 | 2025 | |
| Rxsight INC | $82.55 | 2024-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Visionix USA, INC | $46.88 | 2022 | |
| Glaukos Corporation | $27.78 | 2019 | |
| Alcon Vision LLC | $21.05 | 2021 | |
| Lombart Brothers, INC. | $20.61 | 2023 | Opd-III |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Macedo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.